Does dalcetrapib reduce the risk of recurrent cardiovascular events in patients with a recent acute coronary syndrome?
Patients with a recent acute coronary syndrome
Dalcetrapib
Recurrent cardiovascular eventshard clinical
Dalcetrapib successfully raises HDL cholesterol but does not translate to a reduction in recurrent cardiovascular events after an acute coronary syndrome.
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Gregory G. Schwartz
Anders Olsson
Markus Abt
New England Journal of Medicine
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
University of Toronto
Baylor College of Medicine
Université de Montréal
Building similarity graph...
Analyzing shared references across papers
Loading...
Schwartz et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69effa394f6a06657c21defe — DOI: https://doi.org/10.1056/nejmoa1206797